{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:40:25Z","timestamp":1792687225145,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tianjin Institute of Urology Talent Support Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Loss of primary cilia is common in cancer, but its relevance to molecular subtypes of muscle-invasive bladder cancer (MIBC) is unclear. Here, we combined transcriptomic and co-expression analyses with experiments in bladder cancer cell lines, human tumor specimens, and xenografts to investigate the basis of cilia loss in basal MIBC. Primary cilia were less frequent in basal than in luminal MIBC. Depletion of IFT88 reduced ciliogenesis and increased cell proliferation and migration. Conversely, IFT88 overexpression restored cilia, delayed the appearance of palpable xenografts, and limited xenograft growth. NEK2 was enriched in basal MIBC, and higher expression in TCGA was associated with shorter disease-free survival. In basal bladder cancer cells, NEK2 knockdown increased IFT88 abundance and cilia formation and reduced proliferation and migration; NEK2 overexpression had the opposite effects. Rescue experiments showed that these effects of NEK2 depended on IFT88. NEK2 interacted with IFT88, increased its ubiquitination, and accelerated its proteasomal turnover. AURKA knockdown reduced IFT88 ubiquitination after NEK2 overexpression and attenuated the associated cilia loss, proliferation, and migration, whereas AURKA overexpression reversed the effects of NEK2 knockdown. In a xenograft experiment, pretreating IFT88-overexpressing cells with the NEK2 inhibitor JH295 produced the greatest reduction in tumor establishment and growth among the four conditions tested. These data identify a NEK2-AURKA-IFT88 pathway that promotes ubiquitin-dependent IFT88 degradation and cilia loss in basal MIBC models, providing a preclinical basis for further testing of NEK2 targeting in cilia-deficient basal MIBC.<\/jats:p>","DOI":"10.1038\/s41419-026-09203-0","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:15:08Z","timestamp":1787386508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NEK2-AURKA axis drives ubiquitin-dependent IFT88 degradation to suppress ciliogenesis and promote basal-type bladder cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"E","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjiong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5788-3479","authenticated-orcid":false,"given":"Zhihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0607-9480","authenticated-orcid":false,"given":"Changwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2682-9063","authenticated-orcid":false,"given":"Jingxian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"9203_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41576-023-00587-9","volume":"24","author":"P Mill","year":"2023","unstructured":"Mill P, Christensen ST, Pedersen LB. Primary cilia as dynamic and diverse signalling hubs in development and disease. Nat Rev Genet. 2023;24:421\u201341.","journal-title":"Nat Rev Genet"},{"key":"9203_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04118-2","volume":"21","author":"J Li","year":"2023","unstructured":"Li J, Qi Y, Li B, Liu Y, Yang K, Zhang Z, et al. STIL\/AURKA axis promotes cell proliferation by influencing primary cilia formation in bladder cancer. J Transl Med. 2023;21:281.","journal-title":"J Transl Med"},{"key":"9203_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.804419","volume":"10","author":"J Li","year":"2022","unstructured":"Li J, Yang Z, Qi Y, Liu X, Liu Y, Gao X, et al. STIL Acts as an Oncogenetic Driver in a Primary Cilia-Dependent Manner in Human Cancer. Front Cell Dev Biol. 2022;10:804419.","journal-title":"Front Cell Dev Biol"},{"key":"9203_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2020.111952","volume":"390","author":"Y Qie","year":"2020","unstructured":"Qie Y, Wang L, Du E, Chen S, Lu C, Ding N, et al. TACC3 promotes prostate cancer cell proliferation and restrains primary cilium formation. Exp Cell Res. 2020;390:111952.","journal-title":"Exp Cell Res"},{"key":"9203_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/2046-2530-3-7","volume":"3","author":"I Menzl","year":"2014","unstructured":"Menzl I, Lebeau L, Pandey R, Hassounah NB, Li FW, Nagle R, et al. Loss of primary cilia occurs early in breast cancer development. Cilia. 2014;3:7.","journal-title":"Cilia"},{"key":"9203_CR6","doi-asserted-by":"publisher","first-page":"e68521","DOI":"10.1371\/journal.pone.0068521","volume":"8","author":"NB Hassounah","year":"2013","unstructured":"Hassounah NB, Nagle R, Saboda K, Roe DJ, Dalkin BL, McDermott KM. Primary cilia are lost in preinvasive and invasive prostate cancer. PLoS One. 2013;8:e68521.","journal-title":"PLoS One"},{"key":"9203_CR7","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1158\/0008-5472.CAN-24-1095","volume":"84","author":"W Shi","year":"2024","unstructured":"Shi W, Li L, Zhao H, Li Z, Ma Z, Gu Q, et al. Targeting SHCBP1 Inhibits Tumor Progression by Restoring Ciliogenesis in Ductal Carcinoma. Cancer Res. 2024;84:4156\u201372.","journal-title":"Cancer Res"},{"key":"9203_CR8","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41388-025-03416-x","volume":"44","author":"R Collinson","year":"2025","unstructured":"Collinson R, Tanos B. Primary cilia and cancer: a tale of many faces. Oncogene. 2025;44:1551\u201366.","journal-title":"Oncogene"},{"key":"9203_CR9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/nm.2011","volume":"15","author":"SY Wong","year":"2009","unstructured":"Wong SY, Seol AD, So PL, Ermilov AN, Bichakjian CK, Epstein EH Jr., et al. Primary cilia can both mediate and suppress Hedgehog pathway-dependent tumorigenesis. Nat Med. 2009;15:1055\u201361.","journal-title":"Nat Med"},{"key":"9203_CR10","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/nm.2020","volume":"15","author":"YG Han","year":"2009","unstructured":"Han YG, Kim HJ, Dlugosz AA, Ellison DW, Gilbertson RJ, Alvarez-Buylla A. Dual and opposing roles of primary cilia in medulloblastoma development. Nat Med. 2009;15:1062\u20135.","journal-title":"Nat Med"},{"key":"9203_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskjot","year":"2023","unstructured":"Dyrskjot L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, et al. Bladder cancer. Nat Rev Dis Primers. 2023;9:58.","journal-title":"Nat Rev Dis Primers"},{"key":"9203_CR12","first-page":"11536","volume":"24","author":"G Facchini","year":"2020","unstructured":"Facchini G, Cavaliere C, Romis L, Mordente S, Facchini S, Iovane G, et al. Advanced\/metastatic bladder cancer: current status and future directions. Eur Rev Med Pharmacol Sci. 2020;24:11536\u201352.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"9203_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","volume":"21","author":"L Tran","year":"2021","unstructured":"Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D. Advances in bladder cancer biology and therapy. Nat Rev Cancer. 2021;21:104\u201321.","journal-title":"Nat Rev Cancer"},{"key":"9203_CR14","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reynies A, Allory Y, Sjodahl G, Robertson AG, Seiler R, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020;77:420\u201333.","journal-title":"Eur Urol"},{"key":"9203_CR15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, et al. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol. 2017;72:544\u201354.","journal-title":"Eur Urol"},{"key":"9203_CR16","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","volume":"27","author":"CE Chu","year":"2021","unstructured":"Chu CE, Sjostrom M, Egusa EA, Gibb EA, Badura ML, Zhu J, et al. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clin Cancer Res. 2021;27:5123\u201330.","journal-title":"Clin Cancer Res"},{"key":"9203_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1432586","volume":"15","author":"J Li","year":"2024","unstructured":"Li J, Shan K, Huang W, Su Q, Qi Y, Zhang Z, et al. The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer. Front Immunol. 2024;15:1432586.","journal-title":"Front Immunol"},{"key":"9203_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00418-021-01965-2","volume":"155","author":"P Iruzubieta","year":"2021","unstructured":"Iruzubieta P, Castiella T, Monleon E, Berga C, Munoz G, Junquera C. Primary cilia presence and implications in bladder cancer progression and invasiveness. Histochem Cell Biol. 2021;155:547\u201360.","journal-title":"Histochem Cell Biol"},{"key":"9203_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112850","volume":"42","author":"Z Fang","year":"2023","unstructured":"Fang Z, Li X, Yoshino Y, Suzuki M, Qi H, Murooka H, et al. Aurora A polyubiquitinates the BRCA1-interacting protein OLA1 to promote centrosome maturation. Cell Rep. 2023;42:112850.","journal-title":"Cell Rep"},{"key":"9203_CR20","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L. Advances in diagnosis and treatment of bladder cancer. BMJ. 2024;384:e076743.","journal-title":"BMJ"},{"key":"9203_CR21","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/pnas.1318376111","volume":"111","author":"JS Damrauer","year":"2014","unstructured":"Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA. 2014;111:3110\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9203_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152\u201365.","journal-title":"Cancer Cell"},{"key":"9203_CR23","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017;171:540\u201356.e25.","journal-title":"Cell"},{"key":"9203_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22126-x","volume":"8","author":"NA Marzouka","year":"2018","unstructured":"Marzouka NA, Eriksson P, Rovira C, Liedberg F, Sjodahl G, Hoglund M. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort. Sci Rep. 2018;8:3737.","journal-title":"Sci Rep"},{"key":"9203_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66747-7","volume":"10","author":"CC Guo","year":"2020","unstructured":"Guo CC, Bondaruk J, Yao H, Wang Z, Zhang L, Lee S, et al. Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Sci Rep. 2020;10:9743.","journal-title":"Sci Rep"},{"key":"9203_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s42255-023-00754-6","volume":"5","author":"ME Steidl","year":"2023","unstructured":"Steidl ME, Nigro EA, Nielsen AK, Pagliarini R, Cassina L, Lampis M, et al. Primary cilia sense glutamine availability and respond via asparagine synthetase. Nat Metab. 2023;5:385\u201397.","journal-title":"Nat Metab"},{"key":"9203_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24769-3","volume":"12","author":"X Zhang","year":"2021","unstructured":"Zhang X, Huang X, Xu J, Li E, Lao M, Tang T, et al. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat Commun. 2021;12:4536.","journal-title":"Nat Commun"},{"key":"9203_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9087","volume":"6","author":"S Kim","year":"2015","unstructured":"Kim S, Lee K, Choi JH, Ringstad N, Dynlacht BD. Nek2 activation of Kif24 ensures cilium disassembly during the cell cycle. Nat Commun. 2015;6:8087.","journal-title":"Nat Commun"},{"key":"9203_CR29","first-page":"4068","volume":"142","author":"SJ Endicott","year":"2015","unstructured":"Endicott SJ, Basu B, Khokha M, Brueckner M. The NIMA-like kinase Nek2 is a key switch balancing cilia biogenesis and resorption in the development of left-right asymmetry. Development. 2015;142:4068\u201379.","journal-title":"Development"},{"key":"9203_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000452546","volume":"40","author":"Y Zhu","year":"2016","unstructured":"Zhu Y, Wei W, Ye T, Liu Z, Liu L, Luo Y, et al. Small Molecule TH-39 Potentially Targets Hec1\/Nek2 Interaction and Exhibits Antitumor Efficacy in K562 Cells via G0\/G1 Cell Cycle Arrest and Apoptosis Induction. Cell Physiol Biochem. 2016;40:297\u2013308.","journal-title":"Cell Physiol Biochem"},{"key":"9203_CR31","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1021\/jm200222m","volume":"54","author":"JC Henise","year":"2011","unstructured":"Henise JC, Taunton J. Irreversible Nek2 kinase inhibitors with cellular activity. J Med Chem. 2011;54:4133\u201346.","journal-title":"J Med Chem"},{"key":"9203_CR32","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1474-4422(25)00226-1","volume":"24","author":"V Serpieri","year":"2025","unstructured":"Serpieri V, D\u2019Abrusco F, Valente EM. The relevance of primary cilia in neurological disorders. Lancet Neurol. 2025;24:763\u201375.","journal-title":"Lancet Neurol"},{"key":"9203_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01305-3","volume":"20","author":"R Du","year":"2021","unstructured":"Du R, Huang C, Liu K, Li X, Dong Z. Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy. Mol Cancer. 2021;20:15.","journal-title":"Mol Cancer"},{"key":"9203_CR34","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a Cancer Dependency Map. Cell. 2017;170:564\u201376.e16.","journal-title":"Cell"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09203-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09203-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09203-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:06:23Z","timestamp":1792685183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09203-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9203"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09203-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"16 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"903"}}